Combination of Activating Blood Circulation and Detoxifying Chinese Medicines Played an Anti-Inflammatory Role in Unstable Angina Patients after Percutaneous Coronary Intervention: A Multicenter, Open-Labeled, Randomized Controlled Trial
Back to article page
|Updated:2021-09-24
|
Combination of Activating Blood Circulation and Detoxifying Chinese Medicines Played an Anti-Inflammatory Role in Unstable Angina Patients after Percutaneous Coronary Intervention: A Multicenter, Open-Labeled, Randomized Controlled Trial
Chinese Journal of Integrative MedicinePages: 1-8
Affiliations:
Author bio:
Funds:
Supported by the National Natural Science Foundation of China (No. 81573818 and No. 81774141),Conflict of Interest,The authors declare that they have no conflict of interests.,Author Contributions,Ma XJ and Zhang Y were responsible for data collection and analysis and drafted the manuscript. Gao J and Guan BY contributed to the figures and figure legend in manuscript. Chen KJ, Duan WH and Shi DZ conceived and substantially contributed to the design of the study. WD and DS participated in the modification of manuscript for important intellectual content. All authors read and approved the final manuscript.
DOI:
CLC:
Scan for full text
Xiao-juan Ma, Wen-hui Duan, Ying Zhang, et al. Combination of Activating Blood Circulation and Detoxifying Chinese Medicines Played an Anti-Inflammatory Role in Unstable Angina Patients after Percutaneous Coronary Intervention: A Multicenter, Open-Labeled, Randomized Controlled Trial. [J/OL]. 1-8(0)
DOI:
Xiao-juan Ma, Wen-hui Duan, Ying Zhang, et al. Combination of Activating Blood Circulation and Detoxifying Chinese Medicines Played an Anti-Inflammatory Role in Unstable Angina Patients after Percutaneous Coronary Intervention: A Multicenter, Open-Labeled, Randomized Controlled Trial. [J/OL]. 1-8(0)DOI:
Combination of Activating Blood Circulation and Detoxifying Chinese Medicines Played an Anti-Inflammatory Role in Unstable Angina Patients after Percutaneous Coronary Intervention: A Multicenter, Open-Labeled, Randomized Controlled Trial
Efficacy of Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B Cirrhosis/Liver Fibrosis: A Randomized Double-Blind Controlled Trial
Schisandrin B Protects against Ischemic Brain Damage by Regulating PI3K/AKT Signaling in Rats
Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents: A Randomized Controlled Trial
Polypeptide from Moschus Suppresses Lipopolysaccharide-Induced Inflammation by Inhibiting NF-κ B-ROS/NLRP3 Pathway
Related Author
No data
Related Institution
Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China;Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China;National Center for Infectious Diseases, Beijing, China;Peking University Ditan Teaching Hospital, Beijing, China;Central of Integrated Chinese and Western Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China;China Traditional Chinese Medicine Holdings Co. Limited, Guangzhou, China
Department of Neurology, The First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian Province, China;Department of Neurosurgery, Fujian Medical University Union Hospital, Fuzhou, China
Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China;Acupuncture and Massage College, Shanghai University of Traditional Chinese Medicine, Shanghai, China;Department of Health Management, The First Affiliated Hospital of Nanchang University, Nanchang, China;Jiangxi Provincial Traditional Chinese Medicine Nephropathy Clinical Research Center, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi Province, China;Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China;Institute of Critical Care, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Department of Pharmacology, Southwest Medical University, Luzhou, Sichuan Province, China;Sichuan Institute for Translational Chinese Medicine, Translational Chinese Medicine Key Laboratory of Sichuan Province, Sichuan Academy of Chinese Medicine Sciences, Chengdu, China;Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, College of Pharmacy, Changsha Medical University, Changsha, China;Sichuan Fengchun Pharmaceutical Co., Ltd., Deyang, Sichuan Province, China;Sichuan Ant Recommendation Biotechnology Co., Ltd., Chengdu, China